 
July 13, 2012
Scripps Research Institute Gets $77M to Develop HIV Vaccine
The Scripps Research Institute (SRI) was awarded $77 million over seven years from the National Institute of Allergy and Infectious Diseases (NIAID) to focus on developing an HIV vaccine, according to an SRI statement. NIAID, which is part of the National Institutes of Health, offered two Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) grants to support a coordinated, multidisciplinary team of researchers focused on multipronged approaches to accelerate HIV vaccine development. SRI, a large, independent, nonprofit biomedical research organization, will investigate immune responses that may be able to prevent HIV infection or suppress it in people with the virus. Specifically, scientists will study antibodies and B cells (the cells that produce antibodies) and other components of the immune system. The other CHAVI-ID grant was awarded to Duke University in Durham, North Carolina.
To read the SRI statement, click here.
Search: Durham, North Carolina, Duke University, Scripps Research Institute, National Institute of Allergy and Infectious Diseases, National Institutes of Health, HIV/AIDS Vaccine Immunology and Immunogen Discovery
Scroll down to comment on this story.
Hide comments
Previous Comments:
[Go to top]
|
